Related Experiment Video
Updated: Jan 30, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Current and Emerging Targets in Immunotherapy for Osteosarcoma
Shinji Miwa1, Toshiharu Shirai1,2, Norio Yamamoto1
1Department of Orthopaedic Surgery, Kanazawa University School of Medicine, Kanazawa 920-8640, Japan.
Abstract:
Osteosarcoma is the most common primary malignancy of bone. Although outcomes of patients with osteosarcoma have improved since the introduction of chemotherapy, outcomes of metastatic or unresectable osteosarcomas are still unsatisfactory. To improve osteosarcoma outcomes, the development of novel systemic therapies for osteosarcoma is needed. Since the 1880s, various immunotherapies have been utilized in patients with osteosarcoma and some patients have shown response to the treatment. Based on recent studies about the role of the immune system in malignancies, immunotherapies including immune modulators such as interleukin-2 and muramyl tripeptide, dendritic cells, immune checkpoint inhibitors, and engineered T cells have been utilized in patients with malignancies. Although there are limited reports of immunotherapies for osteosarcoma, immunotherapy is thought to be a promising treatment option for treating osteosarcomas. In this review, an overview of various immunotherapies for osteosarcoma is provided and their potential as adjuvant therapies is discussed.
Insights
Immunotherapy shows promise for osteosarcoma treatment, especially for metastatic or unresectable cases. This review explores various immunotherapies and their potential as adjuvant treatments to improve patient outcomes.
Area of Science:
- Oncology
- Immunology
Background:
- Osteosarcoma is the most common primary bone cancer.
- Current chemotherapy outcomes for metastatic or unresectable osteosarcoma remain unsatisfactory.
- Novel systemic therapies are crucial for improving patient survival rates.
Purpose of the Study:
- To provide an overview of diverse immunotherapies for osteosarcoma.
- To discuss the potential of immunotherapy as an adjuvant treatment for osteosarcoma.
- To highlight the promise of immunotherapy in managing osteosarcoma.
Main Methods:
- Review of existing literature on immunotherapies used in malignancies.
- Analysis of studies involving immune modulators, dendritic cells, immune checkpoint inhibitors, and engineered T cells.
- Exploration of historical and recent applications of immunotherapy in osteosarcoma.
Main Results:
- Immunotherapy has been utilized in osteosarcoma treatment with some documented patient responses.
- Various immunotherapeutic approaches, including immune modulators and cell-based therapies, are being investigated.
- Despite limited reports, immunotherapy is recognized as a promising therapeutic avenue.
Conclusions:
- Immunotherapy represents a significant and promising treatment modality for osteosarcoma.
- Further research into immunotherapy applications could lead to improved outcomes for osteosarcoma patients.
- Immunotherapy holds potential as an effective adjuvant therapy to complement existing treatments.
Related Concept Videos
Tumor Immunotherapy
Emerging Adulthood
Introduction Cardiac Emergencies
Electrical Current
Applications of GIS: Disaster Management and Emergency Response
Current Density

